Abstract:123 While transplantation remains the only potentially useful treatment for end-stage organ failure, immunological rejection of allografts continues to be a major problem. We have investigated if the fate of T cell precursors developing in the thymus may be determined by the presence of allo MHC class I peptides, since T cell receptor-MHC class I / self peptide interaction regulates thymocyte development. This study examined the effects and underlying mechanisms of intrathymic (IT) injection of a short segment of a synthetic immunogenic MHC class I peptide [P-2; Residues 67 - 85] of the hypervariable domain of RT1.A derived from WAG rat [RT1u] on islet graft survival in the WF [RT1u]-to-ACI [RT1a]. The results showed that while IT injection of 150 µg P-2 on day -7 did not prolong graft survival in naive recipients [MST of 14.0 days vs 9.6 days in controls], IT injection of 300 µg or 600 µg P-2 led to normoglycemia and permanent islet survival [>200 days] in 4/6 and 3/5 STZ induced diabetic ACI recipients, respectively. IT injection of 150 µg, 300 µg, or 600 µg P-2 combined with 0.5 ml ALS immunosuppression on day -7 led to 100% permanent islet graft survival [>200 days] compared to MST of 15.0 ± 2.3 days in ALS alone treated controls. Similarly prepared animals rejected 3rd party [BN] islets in an acute fashion, thus demonstrating donor specificity. Intravenous injection of 300 µg P-2 combined with 0.5 ml ALS did not prolong islet allografts. The long-term unresponsive islet allograft recipients challenged with 2nd set grafts accepted permanently 4/4 donor-type cardiac allografts while rejecting 3rd party [Lewis] hearts without rejecting the primary [WF] islets. In analyzing the underlying mechanisms of acquired systemic tolerance, we found no suppresser / regulatory cells in the adoptive transfer studies in tolerant animals at 30 days after IT injection of allopeptides. In contrast, adoptive transfer of 5 × 107 unseparated spleen cells or 2 × 107 purified T-cells obtained from tolerant animals 60 and 120 days after islet transplantation into lightly irradiated [200 rad TBI] ACI led to donor-specific permanent islet graft survival in 75 and 100% animals respectively compared to an MST of 14.5 days in lightly irradiated ACI recipients of unmodified syngenic spleen cells. Our findings suggest that maintenance of acquired thymic tolerance induced by class I MHC allopeptides is dependent on generation of regulatory cells and that this strategy may have potential clinical application in the induction of acquired tolerance.

Tolerance in intestinal transplantation

Immunological complications beyond rejection after intestinal transplantation

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Transplantation tolerance and its outcome during infections and inflammation

Durable mixed chimerism may permit subsequent immunosuppression-free intestinal transplantation-A proof-of-principle study

New concepts in tolerance

Transplantation tolerance

Advances in Transplantation Tolerance

Paneth Cell Alterations During Ischemia-reperfusion, Follow-up, and Graft Rejection After Intestinal Transplantation

Transplant Tolerance: Current Insights and Strategies for Long-Term Survival of Xenografts

Strategies to Achieve Immune Tolerance in Allogeneic Solid Organ Transplantation.

Intestinal transplantation: Significance of immune responses

Tolerance Induction for Xenotransplantation

Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

Progress towards xenogenic tolerance

Suppressor T helper type 17 cell responses in intestinal transplant recipients with allograft rejection

New strategies in immune tolerance induction

Innate and Adaptive Immune Responses in Intestinal Transplant Rejection: Through the Lens of Inflammatory Bowel and Intestinal Graft-Versus-Host Diseases

Xenotransplantation: immunological hurdles and progress toward tolerance

REGULATORY T CELLS MAINTAIN PERIPHERAL TOLERANCE TO ISLET ALLOGRAFTS INDUCED BY INTRATHYMIC INJECTION OF MHC CLASS I ALLOPEPTIDES

Introducing thymus for promoting transplantation tolerance